Winter Park, Florida–(Newsfile Corp. – April 1, 2026) – Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapy, and premium wellness solutions, today announced key highlights from its annual Form 10-K report for the year ended December 31, 2025. a dormant shell to an active player in the high-growth regenerative health sector.
In 2025, Adia Nutrition will reach a total revenue of approximately $700,508, representing a significant increase from only $6,380 in 2024. This growth is driven primarily by sales of biological products (approximately 63%) and medical procedures (approximately 35%) through the Adia Labs and Adia Medd divisions. Gross profit reached $191,670, while the company reported an operating loss of $366,492 and a net loss of $395,464. Management attributes the improved top-line performance to the launch of clinical services, increased sales of biologics, and initial R&D and clinical activities.
“Our 2025 results reflect the successful execution of our strategy to build a scalable platform in regenerative medicine,” said Larry Powalisz, Chief Executive Officer of Adia Nutrition. “Income grew more than 100-fold as we shifted our focus towards high-potential stem cells and biologic offerings. With our recent achievement of full SEC reporting status, we are now positioned for greater transparency, investor confidence, and accelerated growth towards potential uplisting.”
Key Business and Operational Highlights from the 10-K and Recent Developments:
-
Regenerative Medicine Focus: Through Adia Med, the company offers specialty treatments including stem cell therapy for orthopedic conditions, pain management, and wound repair. Adia Med also supports autologous hematopoietic stem cell transplantation (AHSCT) for approved indications such as multiple sclerosis, and platelet-rich plasma therapy (PRP). Adia Labs procures and sells premium biological products like AdiaVita (umbilical cord blood derived stem cells and exosomes) and AdiaLink (amniotic fluid-derived exosomes), both processed in strict FDA Part 361 and AATB standards.
-
Diversified Segment: The company operates through Adia Med (clinical services), Adia Labs (biological sales), and Biolete (nutritional supplements, including protein coffee and mushroom extract). It also holds an equity stake in a parallel nutrition business.
-
Complete SEC Reporting Milestone: In February 2026, Adia’s Form 10 registration statement became effective, making the company a fully reporting entity under the Securities Exchange Act of 1934. This allows for regularly audited disclosures through 10-K, 10-Q, and 8-K filings, in accordance with standards to support NAS business.
-
Operational Infrastructure: The company maintains a clinic and operations in Winter Park, Florida, with a small but focused team supplemented by medical experts on board, including doctors specializing in regenerative therapies.
-
Market Opportunities: Adia is taking advantage of the growing stem cell therapy market, expected to achieve significant growth in the coming years, by emphasizing minimally manipulated allogeneic and autologous products.
#Adia #Nutrition #Reports #Strong #Revenue #Growth #Annual #Report #Highlights #Transition #Regenerative #Medicine #Full #SEC #Reporting #Status